Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 28:3:1158260.
doi: 10.3389/fruro.2023.1158260. eCollection 2023.

Intermittent catheterization: A patient-centric approach is key to optimal management of neurogenic lower urinary tract dysfunction

Affiliations

Intermittent catheterization: A patient-centric approach is key to optimal management of neurogenic lower urinary tract dysfunction

Andrei Krassioukov et al. Front Urol. .

Abstract

The value of disposable, single-use catheters has come under scrutiny in recent years with a growing attention on environmental sustainability. Intermittent catheterization (IC) is a widely available and minimally invasive technique for management of lower urinary tract dysfunction. Effective IC for individuals with neurogenic lower urinary tract dysfunction can promote their independence and improve quality of life. Are there alternative options within IC that could minimize environmental impact without compromising the safety and effectiveness of single-use catheters? How does the future of IC look - environmentally friendly, biodegradable, disposable catheters may be complementary to certified reusable catheters? In the midst of this debate, it is important to emphasize that individuals have the right to choose the best evidence-based treatment available. Here we consider the current landscape for IC with a focus on chronic use in individuals with neurogenic lower urinary tract dysfunction.

Keywords: access to health care; intermittent catheterization; neurogenic lower urinary tract dysfunction; neurourology; patient safety.

PubMed Disclaimer

Conflict of interest statement

AK, BW, DV, VK, MiW and MaW are all part of the Global Expert Panel Advisory Board funded by Coloplast. KB and SI are employed by Coloplast.

References

    1. Panicker JN. Neurogenic bladder: Epidemiology, diagnosis, and management. Semin Neurol (2020) 40:569–79. doi: 10.1055/s-0040-1713876 - DOI - PMC - PubMed
    1. Agochukwu-Mmonu N, Pop-Busui R, Wessells H, Sarma AV. Autonomic neuropathy and urologic complications in diabetes. Auton Neurosci (2020) 229:102736. doi: 10.1016/j.autneu.2020.102736 - DOI - PMC - PubMed
    1. Przydacz M, Denys P, Corcos J. What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? Ann Phys Rehabil Med (2017) 60:341–46. doi: 10.1016/j.rehab.2017.02.008 - DOI - PubMed
    1. Gajewski JB, Drake MJ. Neurological lower urinary tract dysfunction essential terminology. Neurourol Urodyn (2018) 37(S6):S25–31. doi: 10.1002/nau.23758 - DOI - PubMed
    1. Buchter ML, Kjellberg J, Ibsen R, Sternhufvud C, Petersen B. Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study. Expert Rev Pharmacoecon Outcomes Res (2022) 22(6):919–26. doi: 10.1080/14737167.2022.2054804 - DOI - PubMed

LinkOut - more resources